Regenx Reports on Details of the Annual General and Special Meeting
June 12 2024 - 10:36PM
Regenx Tech Corp., (the
"
Corporation" or "
Regenx") (CSE:
RGX) (OTCQB: RGXT) (FSE: YRS WKN: A2DSW3) announces the results of
its Annual General and Special Meeting held today. All the
resolutions proposed to the shareholders detailed in the Management
Information Circular dated the 29th of April, 2024 were duly
passed.
The resolutions which were passed included:
- The following
five (5) incumbent directors were re-elected for the coming
year:
Greg PenduraDarcy
ThieleRick PurdyHarvey GranatierCurtis Sparrow;
- The appointment
of Gallo LLP, Chartered Professional Accountants as Auditors of the
Company;
- The
consolidation of share capital.
Further to its March 26, 2024 and June 10, 2024
news releases, effective on Tuesday, June 18, 2024, the
Corporation will complete the consolidation (the
“Consolidation”) of its Common Shares on the basis
of 2 pre-Consolidation Common Shares for 1 post-Consolidation
Common Share, subject to regulatory approval, including approval
of the Canadian Securities Exchange (the “CSE”).
Where the exchange results in a fractional share, the number of
Common Shares will be rounded up to the next greater whole number
of Common Shares if the fractional entitlement is equal to or
greater than 0.5 and shall, without any additional compensation, be
rounded down to the next lesser whole number of Common Shares if
the fractional entitlement is less than 0.5 and, in calculating
such fractional interests, all Common Shares registered in the name
of and held by such Shareholder shall be aggregated. Shareholder
approval of the Consolidation was obtained at the annual general
and special shareholders meeting held on June 12, 2024. A new CUSIP
number of 75903N208 replaces the old CUSIP number of 603465303,
to distinguish between the pre- and post- consolidated Common
Shares. The Corporation’s name and trading symbol will remain
unchanged.
The Consolidation is being conducted on a
“push-out” basis. Shareholders of the Corporation, with or without
a physical share certificate, do not need to take any action with
respect to the Consolidation. DRS statements for the
post-Consolidation Common Shares will be mailed on or about June
18, 2024. Existing share certificates will be cancelled.
Commencing at the opening of trading on Tuesday,
June 18, 2024, the Common Shares of the Corporation will trade on
a post-Consolidation basis on the CSE. Following the completion of
the Consolidation, there are expected to be 395,508,808
post-Consolidation Common Shares outstanding.
About Regenx
Regenx is positioned for growth in the CleanTech
sector through the development and commercialization of its
environmentally friendly processing technologies for the recovery
of precious metals. Initial focus is the extraction of platinum and
palladium from diesel catalytic converters with its business
partner Davis Recycling. For further information visit
www.Regenx.Tech
For further information contact:
REGENX TECH CORP.Greg PenduraCEO780 800-0726greg@regenx.tech
Forward Looking Statements
This press release contains certain statements
which constitute forward-looking statements or information
(“forward-looking statements”), including statements regarding
Regenx’s business and the Consolidation. Such forward-looking
statements are subject to numerous risks and uncertainties, some
of which are beyond Regenx's control, including the impact of
general economic conditions, the current share price of Regenx's
common shares, and market acceptance of the private placement,
industry conditions, currency fluctuations, the lack of
availability of qualified personnel or management, stock market
volatility and the ability to access sufficient capital from
internal and external sources. Although Regenx believes that the
expectations in its forward-looking statements are reasonable,
they are based on factors and assumptions concerning future
events which may prove to be inaccurate. Those factors and
assumptions are based upon currently available information. Such
statements are subject to known and unknown risks, uncertainties
and other factors that could influence actual results or events
and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward looking
information. As such, readers are cautioned not to place undue
reliance on the forward looking information, as no assurance can
be provided as to future results, levels of activity or
achievements. The forward-looking statements contained in this
document are made as of the date of this document and, except as
required by applicable law, Regenx does not undertake any
obligation to publicly update or to revise any of the included
forward-looking statements, whether as a result of new
information, future events or otherwise. The forward-looking
statements contained in this document are expressly qualified by
this cautionary statement.